Breaking News
Investing Pro 0
Cyber Monday SALE: Up to 54% OFF InvestingPro+ CLAIM OFFER
Close

Sorrento Therape (SRNE)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Sorrento Therape's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.230 -0.120    -8.89%
28/11 - Closed. Currency in USD ( Disclaimer )
After Hours
1.245
+0.015
+1.220%
19:27:41 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 8,786,883
  • Bid/Ask: 1.240 / 1.250
  • Day's Range: 1.220 - 1.370
Sorrento Therape 1.230 -0.120 -8.89%

Sorrento Therape Company Profile

 
Get an in-depth profile of Sorrento Therape, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology
SectorHealthcare
Employees

799

Equity Type

ORD

Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California.

Contact Information

Top Executives

Name Age Since Title
Yue Wu 57 2016 Independent Director
Jaisim Shah 61 2013 Director
Dorman Followwill 58 2017 Lead Independent Director
David Jakob Lemus 58 2017 Independent Director
Kim D. Janda 63 2012 Chair of Scientific Advisory Board & Director
Henry H. Ji 58 2006 Chairman, President & CEO
Tammy Reilly 60 2022 Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

SRNE Comments

Write your thoughts about Sorrento Therape
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Johann Stefan
Johann Stefan Nov 16, 2022 4:22AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
last time I invested to this stock at ~14$. Now, I am owner again. :)
DPP TCR
DPP TCR Nov 16, 2022 4:22AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
waiting for it to get back to $14 again, that would be great!
Johann Stefan
Johann Stefan 17 hours ago
Saved. See Saved Items.
This comment has already been saved in your Saved Items
DPP TCR  oh yes, 1,3 :)
DPP TCR
DPP TCR Oct 10, 2022 12:26PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
1.35 sheesh!! 52 week low of 1.15 might be coming in, i really do not want to go bankrupt. Come on SRNE show some magic by christmas!
DPP TCR
DPP TCR Sep 21, 2022 12:37PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
1.70 again, ouch!
DPP TCR
DPP TCR Aug 30, 2022 12:51PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
jeez what a beating, is it never gonna end?
DPP TCR
DPP TCR Jun 11, 2022 12:47AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
so took the 'a' out of the *****
DPP TCR
DPP TCR Jun 11, 2022 12:47AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
they bleeped out the word 'rectl' cancer
DPP TCR
DPP TCR Jun 11, 2022 12:46AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Dostarlimab from the pharmaceutical company GlaxoSmithKline acheives 100% success in treating patients with *******cancer - 14 patients in one study show no form of *******cancer after the treatment. Wonder what our guys at SRNE are doing, other companies are getting their magic bullets. Good lord if any of you guys own GlaxoSmithKline, good on ya, thats going to get you set for the start of a good life. Hope SRNE jumps on the bandwagon soon enough.
Robert Poot
Robert Poot May 25, 2022 8:44PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I just bought another 1000 shares. research says its a bargain, value = 3.4 a share
DPP TCR
DPP TCR May 25, 2022 8:44PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Respect buddy, average it out.I would love to have my cost price at $1.60, but would need to buy 200,000 shares! haha
Matt Skinner
Matt Skinner May 02, 2022 10:52AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This compny will reverse split before you see 3 agian just sell.
mark slaughter
mark slaughter May 02, 2022 10:52AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
You must be shorting the stock
DPP TCR
DPP TCR Apr 29, 2022 11:24AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Gents I've gotta level with you, as Crim Jamer mentioned on 18th April 2022, the possibility of SRNE going below $1 seems very much likely...If I had the cash I would definitely buy more and average but the fact is for this to come back to a solid $10 and above range is going to be a waiting period of at least 5 years..hoping the time period is less but things look really f88ked up, pretty much operators manipulating the stock to have us sell off and they can reap this really cheap and then enjoy selling it out at anywhere between $12 - $18, while we look on as twits. Those who can average they should, those who can't lets wait it out.
mark slaughter
mark slaughter Apr 29, 2022 11:24AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What are you??… a human crystal ball!?!?… 5 years???🤔… you think its gonna be 5 years before anything is approved??
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email